Vesalius has provided $4.7m to Forendo Pharma, whose existing shareholders also include Karolinska Development, Novartis, Novo and Merck Group.

Forendo Pharma, a Finland-based gynaecological therapy based on research from University of Turku, secured €4m ($4.7m) in funding on Wednesday from Vesalius Biocapital III Partners, a growth-stage vehicle managed by VC firm Vesalius Biocapital Partners. Forendo Pharma focuses on the development of therapies for disorders affecting the organs in the female pelvic and abdominal regions.…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.